Alerta

METHODS AND COMPOSITIONS FOR USING EXTRACELLULAR PARTICLES TO DETECT PATHOLOGY-RELATED PATHWAYS

Resumen de: WO2025085755A1

Disclosed are methods of detecting or quantifying a pathology -related or pathology-protective-pathway in a subject comprising combining a first ligand with a sample obtained from the subject comprising an extracellular particle, wherein the first ligand binds to a cell-type specific marker on the extracellular particle; combining a second ligand with the sample, wherein the second ligand binds to a pathology-related or pathology-protective pathway molecule on the extracellular particle; combining a donor bead to the sample, wherein the donor bead binds to the first ligand or second ligand; combining an acceptor bead to the sample, wherein the acceptor bead binds to the first ligand or second ligand, wherein the donor bead and acceptor bead do not bind to the same ligand; triggering the donor bead to activate the acceptor bead to produce a signal; wherein the amount, presence, or absence of a signal indicates the amount, presence, or absence of a pathological condition in the subject.

EXTRACELLULAR VESICLE COMPOSITIONS AND USES THEREOF

Resumen de: WO2025081242A1

The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.

溶酶体功能轴的神经退行性疾病血液标志物组合及试剂盒

Resumen de: CN122631903A

0001 本发明公开了溶酶体功能轴的神经退行性疾病血液标志物组合及试剂盒，涉及生物医学检测技术领域。该标志物组合由以下三类共7个标志物组成：葡萄糖脑苷脂酶和组织蛋白酶D；鞘脂和神经节苷脂；以及磷酸化tau‑217蛋白、神经丝轻链蛋白和胶质纤维酸性蛋白。本发明还提供了一种体外诊断试剂盒，包含检测上述标志物的特异性试剂，并构建了基于逻辑回归或随机森林算法的风险评估模型。所述标志物组合及试剂盒可用于阿尔茨海默病、帕金森病及神经性戈谢病等神经退行性疾病的早期筛查、鉴别诊断、疾病进展预测及药物疗效监测，具有高灵敏度、高特异性和微创检测的优势。

表位分子印迹膜库的构建结合场效应晶体管用于检测超灵敏生物检测的方法

Resumen de: CN122631731A

0001 本发明公开了表位分子印迹膜库的构建结合场效应晶体管用于检测超灵敏生物检测的方法，用于多种生物分子的检测；同时将制备的表位分子印迹膜库与场效应晶体管技术相结合开发一种高灵敏生物检测的方法，属于生物传感器技术领域；通过在铜箔表面制备分子印迹膜，并且印迹不同的肽段分子从而建立分子印迹膜库；在铜箔刻蚀去除后将膜转移到石墨烯表面构建场效应晶体管，借助石墨烯的高灵敏可以实现不同分子的检测；肽段或蛋白可以进入到分子印迹的特异性空腔中，进而引起电信号的变化，实现生物分子的放大检测；该发明首次实现表位分子印迹膜库的建立，证明了方法的通用性，实现了多种生物样品的高特异性，快速、超敏的检测。

基于磁性SERS编码探针与单线捕获的多重生物标志物同步检测方法及系统

Resumen de: CN122631877A

本发明公开了一种基于磁性SERS编码探针与单线捕获的多重生物标志物同步检测方法及系统，采用Aβ40磁性SERS编码探针、Aβ42磁性SERS编码探针和p‑tau‑181磁性SERS编码探针构成的混合探针与待测血液样本共同孵育，配合磁富集与分离，将LFIA试纸条的检测限降至fg/mL级别；Aβ40磁性SERS编码探针、Aβ42磁性SERS编码探针和p‑tau‑181磁性SERS编码探针标记的三种不同拉曼信号分子特征拉曼峰彼此无重叠，LFIA试纸条的T线同时包被三种特异性捕获抗体，一次层析、一次光谱采集即可同步定量检测三种标志物；优点是能够同时实现血液样本中的三种生物标志物的高灵敏度、高特异性、快速、同步定量检测。

一种快速去除非糖肽而分离或富集糖肽的方法及应用

Resumen de: CN122628125A

本发明提供一种通过吸附并快速去除非糖肽、无机盐离子和小分子分离或富集糖肽的方法及其应用。该方法的优点如下：1、快速，30秒去除非糖肽、无机盐离子、小分子；2、尤其适用于发现低丰度糖蛋白；3、操作简单；4、能够分离或富集四种糖蛋白：N‑连接糖蛋白、O‑连接糖蛋白、C‑连接糖蛋白和GPI锚定糖蛋白；5、成本低；6、大批量分离和富集糖肽。该方法的具体应用：1、鉴定糖蛋白和确定糖基化位点；2、发现新的信号通路；3、检测多种与糖蛋白有关的疾病和疾病康复后的检测。

用于磷酸化Tau蛋白pTau217检测的抗体、免疫检测方法及应用

Resumen de: CN122628189A

0001 本申请公开了一种用于磷酸化Tau蛋白pTau217检测的抗体、免疫检测方法及应用。本申请抗体包括T217‑3D6抗体；T217‑3D6的轻链CDR1、CDR2和CDR3依序为SEQ ID NO.1至3所示序列，重链CDR1、CDR2和CDR3依序为SEQ ID NO.4至6所示序列。基于本申请抗体对磷酸化Tau蛋白pTau217进行免疫检测，操作简单、灵敏度高、特异性强，可实现磷酸化Tau蛋白pTau217快速检测，对评估Tau蛋白磷酸化水平和Tau蛋白pTau217磷酸化相关检测具有重要意义。

用于诊断HIV相关无症状神经认知障碍的外泌体特征蛋白组合物及其应用

Resumen de: CN122631899A

0001 本发明公开了一种用于诊断HIV相关无症状神经认知障碍（ANI）的外泌体特征蛋白组合物，包括以下特征蛋白：DSCAM、IGF1、CAMK2D、UPF1、ALDH2、EIF5A；与非ANI人群相比，ANI人群中DSCAM和IGF1的相对丰度升高，CAMK2D、UPF1、ALDH2和EIF5A的相对丰度降低。该外泌体特征蛋白组合物具有以下优势：（1）诊断精准度高，能够全面覆盖ANI病理机制核心通路，可精准识别ANI患者；（2）特异性强，可清晰反映ANI患者外泌体蛋白的特异性表达模式，从而有效区分ANI与NCI及健康人群；（3）无创便捷，可基于外周血浆进行检测，提高受试者依从性，适合大规模筛查和长期随访；（4）易临床转化：针对上述外泌体特征蛋白制备的试剂盒操作简便，可规模化生产和使用，在各级医院、疾控中心均可落地，适宜推广应用。

一种通用表位分子印迹膜转移到二维表面构建场效应晶体管用于检测生物标志物的方法

Resumen de: CN122631732A

本发明公开了一种通用表位分子印迹膜转移到二维表面构建场效应晶体管用于检测生物标志物的方法，基于在铜箔表面制备表位印迹膜，刻蚀去除铜箔后将其转移到二维材料表面制备成场效应晶体管的生物检测方法，属于生物传感器技术领域；首先将糖化氨基酸序列作为表位分子，并通过硼酸亲和力固定到铜箔表面；通过能够与模板相互作用的多种功能单体印迹形成膜；刻蚀去除铜箔基底，即得到独立的表位分子印迹膜，该膜可以转移到任何二维材料表面；该发明首次实现表位分子印迹膜的转移，并充分利用了分子印迹的高选择性，以及二维材料的超灵敏特点，可实现生物样品的高特异性，快速、超敏的检测。

用于HIV相关无症状神经认知障碍诊断的代谢组学-肠道微生物标志物组合及其应用

Resumen de: CN122629217A

0001 本发明公开了一种用于HIV相关无症状神经认知障碍（ANI）诊断的代谢组学‑肠道微生物标志物组合，包括代谢组学标志物和肠道微生物标志物，其中代谢组学标志物包括血浆标志物和粪便标志物，血浆标志物包括Asp‑Asn和花生四烯酸，粪便标志物包括组氨酸、赖氨酸、鸟氨酸以及吲哚乳酸；肠道微生物标志物包括门水平标志物和属水平标志物，门水平标志物包括厚壁菌门、放线菌门以及变形菌门微生物，属水平标志物包括普拉梭菌属、小杆菌属、克雷伯氏菌属以及普雷沃氏菌属。该标志物组合整合了代谢组学与肠道微生物的核心差异特征，诊断特异性和敏感性高，能够有效区分ANI患者与CI患者及健康人群，为HAND靶向干预提供了明确靶点，具有重要的临床应用价值。

用于鉴定疾病相关RNA和RNA结合蛋白(RBP)相互作用以进行诊断和治疗选择的方法

Resumen de: WO2025122653A1

The present disclosure provides methods for simultaneously identifying dynamic and disease-associated RNA binding protein (RBP)-RNA interaction (PRI) sites at single nucleotide resolution across the entire transcriptome. The methods disclosed herein recapitulates PRI profiles obtained with several distinct conventional PRI methods in a single assay at efficiencies that are improved by orders of magnitude, and permit the identification of the specific RBP bound at a PRI.

プラズマローゲンの低減されたレベルに関連する出生後状態の動物モデル

Resumen de: WO2025035206A1

The invention describes a transgenic, non-human animal model, for testing post-natal, conditionally inducible plasmalogen deficiency. The animal model's genome is equipped with a gene that is capable of regulating the plasmalogen biosynthetic pathway, where the gene has a regulatory region. Within the regulatory region there is at least one conditionally inducible gene editing site that blocks the expression of the gene when edited. The genome also has a nucleic acid editing sequence integrated at a separate locus from the gene which encodes a gene product. The gene product edits the gene editing site when conditionally induced that eventually down-regulates or disrupts the plasmalogen biosynthetic pathway. Methods and uses involving the transgenic, non-human animal model are also provided.

神経疾患、特に運動ニューロン疾患のためのペプチドバイオマーカー

Resumen de: WO2025032091A1

The present invention relates to a splice variant of a CERT1 protein that acts as a biomarker for a TDP-43 pathology, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), but also other neurological diseases, such as Alzheimer's disease. In particular, the present invention relates to methods for identifying a splice variant of CERT1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject and to methods for predicting whether a therapy is likely to be successful. Also claimed are antibodies binding to the CERT1 splice variant and kits comprising the antibody.

Method for constructing a mouse animal model of levodopa-induced dyskinesia

Resumen de: KR20260127477A

0001a 본 발명은 8주령 마우스의 흑색질에 알파-시누클레인 돌연변이 유전자를 갖는 바이러스 AAV-A53T를 흑색질에 정위 주입하여 파킨슨병 모델을 유도하는 단계(1); 상기 (1)단계의 바이러스 주입 2주 후, MPTP를 주입하여 미토콘드리아 기능부전을 더 유도하는 단계(2); 및 상기 (2)단계의 MPTP 주입 8일째부터 3일 간격으로 레보도파 및 카르비도파를 1일 2회 정맥주입하여 운동이상증을 유도하는 단계(3);를 포함하는 것을 특징으로 하는 레보도파로 유도된 운동이상증 마우스 동물 모델 구축 방법을 제공하며, 이전의 이상운동증 마우스 모델과 비교하여 레보도파에 의하여 유도된 비정상적인 불수의 운동이 현저히 증가된 모델을 제공함으로써 이상운동증의 치료제 연구에 기여할 수 있다.

用于诊断阿尔茨海默病的靶标及其检测方法

Resumen de: CN122609706A

本发明属于及医学诊断领域，具体而言，涉及阿尔茨海默病的诊断标志物及其应用。具体地，本发明提供了用于诊断阿尔茨海默病的靶标及其检测方法。更具体地，本发明涉及用于检测样品中UBE2D1基因表达水平的试剂在制备用于诊断阿尔茨海默病或预测阿尔茨海默病风险的组合物或试剂盒中的用途，其中，所述用于检测样品中UBE2D1基因表达水平的试剂包括：用于检测样品中UBE2D1基因的mRNA水平的试剂，用于检测样品中泛素结合酶E2D1水平或泛素结合酶E2D1相关调控蛋白水平的试剂，用于检测UBE2D1基因CpG岛甲基化水平的试剂，或其任意组合。

甘油磷脂代谢物在阿尔茨海默病中的应用

Resumen de: CN122612935A

本发明提供甘油磷脂代谢物在阿尔茨海默病中的应用。本发明从运动重塑5×FAD小鼠粪便代谢谱为切入点，系统分析了运动干预后代谢网络的整体变化特征，结果证实4种特定的甘油磷脂代谢物（PC(18:0/0:0)、PC(18:1(11Z)/0:0)、PC(0:0/16:0)或PC(16:0/0:0)）是运动调控肠脑病理的重要代谢信号分子，具有开发成阿尔茨海默病诊断试剂盒及治疗阿尔茨海默病药物的潜力。

咪唑二肽中的至少一种在制造用于逻辑记忆的改善的经口营养组合物中的用途

Resumen de: KR20160146760A

0001 An anti-aging agent derived from a natural product is provided. At least one selected from the group consisting of imidazolidine peptides and metabolites thereof. The present invention also provides an agent for improving neuropsychological function comprising at least one selected from the group consisting of imidazocidepeptides and metabolites thereof as an active ingredient. The present invention is also directed to an agent for modulating the expression of a transporter, such as SLC23A2, containing at least one selected from the group consisting of imidadocidepeptides and metabolites thereof, an imidazocidepeptide and a metabolite thereof An agent for controlling the concentration of cytokine such as IP-10 containing at least one in blood, an expression analysis method for detecting improvement or deformation of neuropsychological function, a kit for detecting improvement or deformation of neuropsychological function .

一种血清α-突触核蛋白种子体外扩增检测方法、试剂盒及其应用

Resumen de: CN122612933A

0001 本发明公开了一种血清α‑突触核蛋白种子体外扩增检测方法、试剂盒及其应用，属于生物医学领域。本发明提供的血清α‑突触核蛋白种子体外扩增检测方法包括以下步骤：将待测血清裂解，离心后收集第一上清液；所述第一上清液经有机溶剂萃取脂质，收集水相；所述水相加入蛋白酶K消化，再次离心后收集第二上清液；所述第二上清液经超滤后收集截留液，得到预处理后的种子富集血清样本；将所述预处理后的种子富集血清样本加入反应液中进行SAA扩增反应。本发明基于新的血清预处理思路和优化的SAA扩增反应条件，提出了一种新的血清α‑突触核蛋白种子体外扩增检测方法及配套试剂盒，以满足标准化、高通量、跨中心一致性的临床检测需求。

一种皮肤间质液中褪黑素的在体检测微针贴片技术及其制备方法

Resumen de: CN122604364A

0001 本发明提供了一种皮肤间质液中褪黑素的在体检测微针贴片技术及其制备方法，涉及生物医用材料和器械技术领域。本发明提供了一种检测皮肤间质液中褪黑素的体外微针贴片的制备方法，包括以下步骤：将固体微针贴片放入浓度为2~100 μg/mL兔抗人褪黑素IgG溶液中进行包被，得体外微针贴片；所述固体微针贴片选自聚苯乙烯微针贴片或环氧树脂微针贴片。本发明制备方法能够使得体外微针贴片定量检测皮肤间质液中微量的、特定的褪黑素蛋白，具有高灵敏度、高准确性。

用于诊断或辅助诊断绝经后女性认知障碍的试剂盒及应用

Resumen de: CN122612931A

0001 本发明涉及绝经后女性认知障碍诊断技术领域，公开了一种用于诊断或辅助诊断绝经后女性认知障碍的试剂盒及应用。该试剂盒包括用于检测血浆中GFAP、p‑tau181、Orexin‑A等生物标志物表达水平的检测试剂。本发明首次发现并验证了GFAP、p‑tau181等生物标志物在更年期女性认知障碍患者中显著高表达，可作为诊断或辅助诊断的标志物，为绝经后女性认知障碍的早期诊断提供了一种新的、非侵入性的检测手段。

BUTYROPHILIN A2 AND RELATED ISOFORMS FOR THE TREATMENT OF AUTOIMMUNITY AND INFLAMMATION

Resumen de: US20260242441A1

Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.

PEPTIDE DECORATED NANOPARTICLES FOR ENRICHMENT OF SPECIFIC PROTEIN SUBSETS

Resumen de: US20260243777A1

0000 The present disclosure provides a range of compositions and methods for enriching subsets of complex biological samples. Aspects of the present disclosure provide peptide-functionalized particles comprising affinities for subsets of biomolecules from complex biological samples. The present disclosure further provides methods for utilizing functionalized particles to fractionate and analyze complex biological samples.

METHODS FOR THE DIAGNOSIS AND TREATMENT OF PRECLINICAL ALZHEIMER'S DISEASE

Resumen de: WO2026173983A1

The present invention provides methods and biomarkers useful for detecting, diagnosing and treating Alzheimer's Disease. The biomarkers for diagnoses may be used to develop treatment plans for subjects. The methods may be used to diagnose a subject prior to clinical onset of symptoms and may allow for early treatment which may slow progression of the disease.

COMPOSITIONS AND METHODS TO CONTROL LIPOKINE CONCENTRATIONS IN AGE-RELATED DISORDERS

Resumen de: WO2026174301A1

The present disclosure relates to compositions and methods for regulating lipokines in age-related disorders and methods of use thereof.

THERAPEUTIC TARGETING OF TUMOR ESCAPE BY CAR-MEDIATED TROGOCYTOSIS

Nº publicación: US20260241002A1 20/08/2026

Solicitante:

UNIV OF MARYLAND BALTIMORE [US]
University of Maryland, Baltimore

Resumen de: US20260241002A1

Populations of CAR T cells that exhibit reduced trogocytosis are disclosed, as well as methods for making such cells and methods of using such cells in the treatment of cancer. A reduction in trogocytosis is achieved by inhibiting Cathepsin B in the CAR T cells and/or inducing ubiquitylation of cancer antigens taken up by the CAR T cells.